| Date | Title | Description |
| 20.09.2024 | Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the p... |
| 16.09.2024 | Life Sciences Virtual Investor Forum Agenda Announced for September 19th | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda f... |
| 29.08.2024 | Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London | PISCATAWAY, N.J., Aug. 29, 2024 /PRNewswire/ -- The cell and gene therapy (CGT) industry has witnessed remarkable growth in recent years. According to an analysis by RSM US LLP, CGT therapies accounted for 10% of all FDA-approved drugs last... |
| 04.08.2024 | Neuralink's Bold Leap: A New Era for Paralyzed Patients | Neuralink is pushing the boundaries of technology and medicine. The company, founded by Elon Musk, has successfully implanted a brain chip in a second patient. This device aims to empower paralyzed individuals to control digital devices usi... |
| 04.08.2024 | Neuralink implanted second trial patient with brain chip, Musk says | Future of HealthNeuralink implanted second trial patient with brain chip, Musk says
By Rachael LevyAugust 4, 20247:17 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Neuralink logo and Elon Musk... |
| 23.12.2022 | Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma | - Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor -
-Synovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint with an overall response rate of ~39% af... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 15.09.2022 | Sarcoma Foundation of America Honors Adaptimmune Therapeutics with 2022 Vision of Hope Award | Adaptimmune Therapeutics has been selected to receive the 2022 Vision of Hope Award during SFA’s Stand Up to Sarcoma Gala on September 28, 2022, in New York, NY.
Adaptimmune’s contribution to improving sarcoma patient outcomes is extraordin... |
| 15.11.2021 | Here’s Why Roche Stock May Continue To Trend Higher | Logo on building exterior at the Silicon Valley headquarters of pharmaceutical company Roche, Santa ... [+] Clara, California, August 17, 2017. (Photo via Smith Collection/Gado/Getty Images) Getty Images |
| 08.09.2021 | Covid-19 roundup: Gates Foundation, Exscientia team up on pandemic antiviral discovery pact; Novavax opens trial for coronavirus/flu combo vaccine | UK-based AI discovery outfit Exscientia has signed its name to a $70 million collaboration with the Bill and Melinda Gates Foundation to drum up five antiviral candidates for use against coronaviruses and potential pa... |
| 08.09.2021 | Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway | A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing against cancer.
Diaccurate has in-licensed Merck KGaA’s M2698 — now dubbed DIACC3010... |
| 08.09.2021 | As bluebird plans its big split, rare disease head Andrew Obenshain recruits Ironwood vet as CFO | As Nick Leschly counts down his final month as chief bluebird — before taking on the new role of 2seventy CEO — he has unveiled a key hire and a couple of updates.
Gina Consylman
The planned spinout, which is now set to take pl... |
| 08.09.2021 | A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round | Cancer player MacroGenics scored a big win with its full approval for anti-HER2 drug Margenza last winter based on a head-to-head matchup with breast cancer titan Herceptin. Now, a fuller look at Margenza’s survival data months after that a... |
| 08.09.2021 | Looking for fresh start following a Duchenne disaster, Catabasis rebrands; Huadong and Insilico team up in oncology | The leaders of Catabasis Pharmaceuticals have decreed that the biotech’s name is no more. Catabasis will be rebranding to Astria Therapeutics effective immediately, with the company’s stock ticker being updated on ... |
| 08.09.2021 | Years after Pfizer passed on a buyout option, AM-Pharma finds a new partner for its kidney drug | A couple of years ago, Pfizer passed on an option to buy out AM-Pharma and its recombinant human alkaline phosphatase for kidney failure on the heels of some mixed Phase II data. Now, the program has attracted a new partne... |
| 08.09.2021 | A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round | Months after Bay Area startup Attralus tapped Mark Timney to its helm, the ex-Purdue Pharma chief has led the company to a $116 million Series B round — and with it, activist investor Alex Denner is joining the board.
Timney ... |
| 08.09.2021 | With industry's blessing, FDA launches novel excipient review pilot program | The FDA on Tuesday launched a new pilot program that will initially review four novel excipients over two years, with an eye toward helping drug developers in situations where existing excipients may be difficult to... |
| 08.09.2021 | A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round | Tachi is gone, but his legacy biotechs are continuing to make news.
This morning it’s the newly born HilleVax — a creation of Takeda and Frazier Healthcare Partners, where Tachi Yamada was respectively CSO and a longtime partner — that’s ta... |
| 08.09.2021 | Months after landing Canadian site from government, Resilience announces a big mRNA partner | Bob Nelsen
Bob Nelsen’s latest project, dreamed up out of anger, has been focused on becoming the Amazon Web Services of drug manufacturing, with the ability to scale in the most efficient way possible. It has now partnered... |
| 08.09.2021 | Moderna surfaces as the first partner for Jim Wilson's rare disease nonprofit, donating an mRNA program at no cost | Top biopharma execs from Merck, Eli Lilly, Takeda and industry lobbying group PhRMA tried their best to persuade the media Wednesday that drug price negotiation bills making their way through Congress this month will be catastrophic for the... |
| 08.09.2021 | Moderna surfaces as the first partner for Jim Wilson's rare disease nonprofit, donating an mRNA program at no cost | A week after Jim Wilson and Alex Karnal debuted their Tachi Yamada-inspired nonprofit aimed at treating ultra-rare diseases, the partner providing the Institute for Life Changing Medicines with its first pipeline progra... |
| 08.09.2021 | 'Like a kid in a candy shop': Michael Ehlers gets behind RNA 'copy machine' tech | Nathaniel Wang
Nathaniel Wang and Andrew Geall spent years working on self-replicating RNAs at Synthetic Genomics and Novartis Vaccines, respectively, before they realized they were coming at it the wrong way.
“For years an... |
| 07.09.2021 | There's a new anti-aging upstart in town — and it's reportedly backed by Amazon billionaire Jeff Bezos | Despite its standing as pharma’s biggest cancer player, Roche has mostly stood pat on next-gen cell therapies that its competitors have gobbled up with gusto. Ready to finally make a splash of its own, Roche has inked a major deal to dive i... |
| 07.09.2021 | There's a new anti-aging upstart in town — and it's reportedly backed by Amazon billionaire Jeff Bezos | Going to space wasn’t enough. Middle-aged billionaire Jeff Bezos wants to extend human life — and to do so, he’s reportedly backing the latest entrant into Silicon Valley’s burgeoning race to slow aging.
A stealthy biote... |
| 07.09.2021 | Exelixis mourns the deaths of two longtime executives | Exelixis is grieving the loss of two longtime executives this week, one of whom succumbed to a lengthy battle with cancer and the other of whom had been on medical leave since June.
Jon Berndt
Gisela Schwab, Exelixis’ soft-spo... |
| 07.09.2021 | Doubling down on need for mRNA vaccines and mAbs, Avantor puts nearly $3B in pumps and tubing company | Acquisition-happy manufacturer Avantor has positioned itself at the front of the battle against Covid-19, and Tuesday it made another move to embed itself deeper into the ongoing pandemic response.
Pennsylvania-b... |
| 07.09.2021 | Food or drug? FDA blasts Flagship-backed microbiome player’s ‘non-IND’ Covid-19 trial | Hours after the FDA wrapped its marathon listening session on the safety risks of gene therapy, BioMarin offered a reminder of why the advisory committee meeting was convened in the first place.
BioMarin is halting worldwide enrollment to a... |
| 07.09.2021 | Vaccitech makes short move to new headquarters; EnteroBiotix raises more than $21M in Series A | Oxford biotech Vaccitech is moving headquarters — but only about 20 minutes away.
Vaccitech signed a lease for 31,000 square feet within the Zeus development at Harwell Science and Innovation Campus. The firm plans to rel... |
| 07.09.2021 | As tezepelumab awaits FDA decision, Amgen and AstraZeneca tout more data from the Phase III study | The UK’s MHRA may have to lay off about 300 of its 1,200 employees, thanks to a decline in income due to reduced medical product submissions following Brexit, spurring anger among unions across the island.
Five UK unions are now demanding a... |
| 07.09.2021 | There's a new anti-aging upstart in town — and it's reportedly backed by Amazon billionaire Jeff Bezos | Researchers and executives hoping that the FDA’s two-day hearing on gene therapy would offer a clear direction for the field’s future came away disappointed.
For 16 hours, the agency listened to presentations and debated everything from AAV... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | It makes sense to join forces with your partner’s owner.
Japan’s Astellas Pharma is tying up with UK-based Adaptimmune Therapeutics in a deal worth up to $897.5 million to develop stem-cell-derived, off-the-shelf T-cell therapies. Since 201... |
| 01.06.2020 | Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential | The company announced data from its study of the TCR, which targets MAGE-A4 in several solid tumors, with eight of the 16 synovial sarcoma patients achieving partial responses, including one whose response had not been confirmed. Although s... |
| 15.01.2020 | Astellas partners with Adaptimmune in latest move into cell therapy | Most TCRs that have been developed are HLA-restricted, meaning they can only be used in patients with particular genetic profiles. Meanwhile, both FDA-approved CAR-Ts, Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axic... |
| 28.08.2019 | Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership | The deal includes a $75 million investment in the company by Celgene. Immatics would develop TCRs against solid tumor cancers using its in-house technology. It would be responsible for their development and validation through the lead candi... |
| 22.07.2019 | Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study | “These exciting results open a bold new frontier for directing a person’s own immune system to treat patients with solid cancers, an area that hasn’t yet seen the successes of immune cell therapies that we have seen for blood cancers,” said... |
| 06.05.2019 | Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot | Derek Archila
→ Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it didn’t expect to call an advisory panel together to review the newly accepted NDAs for be... |
| 14.12.2018 | Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at Goldfinch | → Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years. Having led Novadip’s autologous cell therapy through a Phase I/IIa tria... |
| 05.09.2018 | What's up at Immunocore?; Pfizer nabs a key 'breakthrough'; Adaptimmune raises $100M | → What’s up at Immunocore? Vantage is reporting that Immunocore’s chief strategy officer Kevin Pojasek is out, marking the latest in a long line of C-suite departure for the company. CEO Eliot Forster was first to depart,... |
| 31.10.2016 | What’s on Sanofi’s M&A list now that Medivation is gone? Catalyst gets an SPA; Adaptimmune partners with Merck | As we’ve said before at Endpoints News, this has been a rough year for Sanofi $SNY. Now that Medivation has slipped through its fingers, falling to Pfizer, CEO Olivier Brandicourt has had to answer fresh questions about its M&... |
| 27.10.2016 | GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO | Andrew Witty, GSK
GlaxoSmithKline didn’t just kill losmapimod on Wednesday. The pharma giant was also forced to dump a late-stage HIV drug acquired from Bristol-Myers late last year in a $1.46 billion deal. Here’s the explan... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 07.05.2015 | Bill and Melinda Gates Foundation putting $75M toward disease surveillance, Roche gets FDA approval for venetoclax (Morning Read) | LIFE SCIENCE
Adaptimmune, a UK-based biotech using T-cell therapy to treat cancer and infectious disease, raised $191 million in its IPO. The company priced 11.3 million shares at the high end of the range ($17 per share) for a market cap o... |
| 02.02.2015 | OrbiMed draws in more healthcare strategics in nearly $1 billion royalty and credit fund | A dozen leading medical research and healthcare institutions contributed to the royalty and credit fund – the most ever, Managing Director Tadd Wessel said. He wouldn’t say how much these strategic partners contributed, but added OrbiMed wa... |
| 17.10.2014 | Report: Funding in runup to biotech and medical device IPOs boosts Q3 investment | There were 23 venture-backed IPOs in the third quarter and 18 of them were biotech and medical device IPOs. One was the first company to commercialize a bionic eye. Second Sight Medical raised about $32 million in an IPO in August.
When it ... |
| 25.09.2014 | Adaptimmune Raises $104m in Venture Capital | Adaptimmune, an Oxford, UK-based biotechnology company, raised $104m in venture capital.
The round was led by New Enterprise Associates with participation from new investors OrbiMed Advisors, Wellington Management Company, Fidelity Bioscien... |
| 20.09.2011 | Adaptimmune announces new Board appointments as clinical programmes get underway | Adaptimmune announces new Board appointments as clinical programmes get underway
20-09-2011
Adaptimmune, which is pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board... |
| 14.06.2011 | Adaptimmune opens Phase I/II clinical trial for metastatic melanoma at US university | Adaptimmune opens Phase I/II clinical trial for metastatic melanoma at US university
14-06-2011
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington Universi... |
| 08.03.2011 | Adaptimmune announces launch of US subsidiary and appointment of Gwen Binder-Scholl as VP... | Adaptimmune announces launch of US subsidiary and appointment of Gwen Binder-Scholl as VP...
08-03-2011
Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwe... |
| - | Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study | A company developing cell therapies in oncology has started dosing patients in an early-stage clinical trial of a product candidate designed to be targeted to proteins in cancer cells unique to each patient.
South San Francisco, California-... |
| - | Report: Funding in runup to biotech and medical device IPOs boosts Q3 investment | The initial public offering window continues to draw a steady stream of investment from venture and private equity investors allocating funding to what’s referred to as the crossover round that precedes an IPO. That was one of the takeaways... |
| - | Bill and Melinda Gates Foundation putting $75M toward disease surveillance, Roche gets FDA approval for venetoclax (Morning Read) | TOP STORIES
The Bill and Melinda Gates Foundation is investing up to $75 million in a network of disease surveillance sites in developing countries to rapidly gather better data, about how, where and why children are getting sick and dying,... |
| - | Astellas partners with Adaptimmune in latest move into cell therapy | Although the two CAR-T cell therapies that the Food and Drug Administration approved in 2017 remain the only ones on the market, a number of companies have busied themselves with their own programs, developing their own capabilities and als... |
| - | OrbiMed draws in more healthcare strategics in nearly $1 billion royalty and credit fund | Healthcare investor OrbiMed announced its second debt and royalty fund on Monday and continued to expand efforts to add more healthcare institutions as investors.
The $924 million OrbiMed Royalty Opportunities II will invest between $20 mil... |
| - | Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential | Data from patients with a form of connective-tissue cancer who participated in a Phase I study of an investigational cell therapy lend support to an ongoing trial that could potentially be used to secure regulatory approval, the company dev... |
| - | Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership | A large biotech company is pouring tens of millions of dollars into a German firm under a partnership to develop cell therapies in oncology.
Immatics Biotechnologies, based near Munich, said Wednesday that it had entered the partnership wit... |
